- Conditions
- HIV Infections
- Interventions
- Cabotegravir Oral Tablet, TDF/FTC tablets, Placebo for TDF/FTC tablets, Placebo for cabotegravir oral tablet, CAB LA, Placebo for CAB LA
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,570 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2025
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2593–2616
of 5,570
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- TAS-102, Bevacizumab
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI), FDC
- Interventions
- Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil, Esomeprazole, amoxicillin-clavulanate
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Budesonide, budesonide/formoterol, Ipratropium/albuterol
- Drug
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Torrance, California • Denver, Colorado + 4 more
- Conditions
- Substance Use Disorders, Opioid Use Disorder, Alcohol Use Disorder, Cocaine Use Disorder, Methamphetamine-dependence
- Interventions
- EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance), CBOT with olfactory stimulants & OFC tasks, CBOT Sham
- Combination Product
- Lead sponsor
- Evon Medics LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Rockville, Maryland
- Conditions
- Liver Neoplasms
- Interventions
- SonoVue-enhanced ultrasound, Unenhanced ultrasound
- Drug · Other
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 349 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Carcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors
- Interventions
- Nivolumab, Cabozantinib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- HIV-1 Infection
- Interventions
- Pravastatin sodium, Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Torrance, California • St Louis, Missouri + 6 more
- Conditions
- Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults, AML (Adult) With 11q23 (MLL) Abnormalities, AML (Adult) With Del (5q), AML (Adult) With Inv (16) (p13; q22), AML (Adult) With t (16;16) (p13; q22), AML (Adult) With t (8; 21) (q22; q22), Secondary AML (Adult), Untreated AML (Adult)
- Interventions
- Decitabine, Midostaurin
- Drug
- Lead sponsor
- David Iberri
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Prostatic Hyperplasia
- Interventions
- dutasteride 0.5mg once daily for 4 years, tamsulosin 0.4mg once daily for 4 years
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 4,844 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 113
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Hoover, Alabama + 98 more
- Conditions
- Microsatellite-stable Colorectal Cancer, Standard of Care, Nivolumab, Bevacizumab
- Interventions
- Nivolumab, Bevacizumab, BMS-986340, Trifluridine + Tipiracil
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cocaine Abuse, Cocaine-Related Disorders
- Interventions
- Modafinil, Levodopa/Carbidopa, Naltrexone HCl, Placebo, Motivational Interviewing (MI), Contingency management (CM), Cognitive-Behavioral Therapy (CBT)
- Drug · Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hyperlipidemia
- Interventions
- SLx-4090, Placebo, Statin
- Drug · Other
- Lead sponsor
- Response Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 14 more
- Conditions
- Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
- Interventions
- SLC-391, pembrolizumab
- Drug · Biological
- Lead sponsor
- SignalChem Lifesciences Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Lafayette, Indiana • Detroit, Michigan + 3 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- carbidopa-levodopa 25-100 mg tablets
- Drug
- Lead sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
- Individual
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only), Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
- Interventions
- Combination of varlilumab and nivolumab
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more
- Conditions
- Microbicide Delivery System Acceptability
- Interventions
- high volume gel, low volume gel, vaginal film
- Other
- Lead sponsor
- The Miriam Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Subjects Requesting and Requiring Facial Rejuvenation With Neurotoxins and/or Hyaluronic Acid Fillers
- Interventions
- NuDerm® System, Placebo
- Other
- Lead sponsor
- DeNova Research
- Other
- Eligibility
- 25 Years to 60 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Second Stage of Labor
- Interventions
- Caffeine and Sodium Benzoate Injection, Normal Saline
- Drug
- Lead sponsor
- The Reading Hospital and Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- West Reading, Pennsylvania
- Conditions
- HIV Infections
- Interventions
- fosamprenavir, COMBIVIR, ritonavir, TRIZIVIR
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Long Beach, California • Newport Beach, California + 8 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Burbank, California • Grand Junction, Colorado + 12 more
- Conditions
- HIV Infections
- Interventions
- MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs
- Drug
- Lead sponsor
- Myrexis Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 21
- States / cities
- Beverly Hills, California • Los Angeles, California • San Francisco, California + 16 more
- Conditions
- Hepatitis C, Chronic, Pregnancy; Infection
- Interventions
- Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
- Drug
- Lead sponsor
- Catherine Anne Chappell
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 6
- States / cities
- Cincinnati, Ohio • Columbus, Ohio • Pittsburgh, Pennsylvania + 3 more
- Conditions
- Opioid Use Disorder
- Interventions
- MORE-VR, Treatment as Usual
- Device · Other
- Lead sponsor
- BehaVR LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- La Jolla, California • Salt Lake City, Utah